These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19903782)

  • 1. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.
    Shariat SF; Karakiewicz PI; Godoy G; Karam JA; Ashfaq R; Fradet Y; Isbarn H; Montorsi F; Jeldres C; Bastian PJ; Nielsen ME; Müller SC; Sagalowsky AI; Lotan Y
    Clin Cancer Res; 2009 Nov; 15(22):7012-9. PubMed ID: 19903782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.
    Karam JA; Lotan Y; Karakiewicz PI; Ashfaq R; Sagalowsky AI; Roehrborn CG; Shariat SF
    Lancet Oncol; 2007 Feb; 8(2):128-36. PubMed ID: 17267327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
    Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
    Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 expression in patients with advanced urothelial cancer of the urinary bladder.
    Shariat SF; Bolenz C; Karakiewicz PI; Fradet Y; Ashfaq R; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Rigaud J; Müller SC; Lerner SP; Montorsi F; Sagalowsky AI; Cote RJ; Lotan Y
    BJU Int; 2010 Feb; 105(4):489-95. PubMed ID: 19659466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder.
    Wang LC; Xylinas E; Kent MT; Kluth LA; Rink M; Jamzadeh A; Rieken M; Al Hussein Al Awamlh B; Trinh QD; Sun M; Karakiewicz PI; Novara G; Chrystal J; Zerbib M; Scherr DS; Lotan Y; Vickers A; Shariat SF
    Urol Oncol; 2014 May; 32(4):433-40. PubMed ID: 24433754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.
    Skagias L; Politi E; Karameris A; Sambaziotis D; Archondakis A; Ntinis A; Moreas I; Vasou O; Koutselini H; Patsouris E
    Anticancer Res; 2009 Oct; 29(10):4163-7. PubMed ID: 19846967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
    Margulis V; Lotan Y; Karakiewicz PI; Fradet Y; Ashfaq R; Capitanio U; Montorsi F; Bastian PJ; Nielsen ME; Müller SC; Rigaud J; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Shariat SF
    J Natl Cancer Inst; 2009 Jan; 101(2):114-9. PubMed ID: 19141773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
    Shariat SF; Ashfaq R; Karakiewicz PI; Saeedi O; Sagalowsky AI; Lotan Y
    Cancer; 2007 Mar; 109(6):1106-13. PubMed ID: 17311310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
    Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer.
    Xi RC; Sheng YR; Chen WH; Sheng L; Gang JJ; Tong Z; Shan Z; Ying GH; Dong LC
    J Surg Oncol; 2013 Apr; 107(5):550-4. PubMed ID: 23090902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.
    Youssef RF; Shariat SF; Kapur P; Kabbani W; Ghoneim T; King E; Cockburn A; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
    Hum Pathol; 2011 Mar; 42(3):347-55. PubMed ID: 21111452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
    Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
    Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
    J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
    Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
    Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
    Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
    J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
    Youssef R; Kapur P; Shariat SF; Arendt T; Kabbani W; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
    BJU Int; 2012 Oct; 110(7):961-6. PubMed ID: 22372762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.